Anda di halaman 1dari 14

Global Anatomic Pathology Market Research and Analysis 2015-2022

OrionOrion
Market Research
Market Research

TABLE OF CONTENTS
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
Medical Devices
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RAW MATERIAL ANALYSIS
2.4. REGULATION
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. BENEFITS OVER CONVENTIONAL DRUG DELIVERY DEVICES
3.1.2. RISING INCIDENCES OF RESPIRATORY DISEASES
3.1.3. TECHNOLOGICAL ADVANCEMENTS
Global 3.1.4.
Anatomic Pathology
INCREASING GERIATRICMarket Research and Analysis 2015-
POPULATION

2022 3.1.5. RISE IN CONSTRUCTION INDUSTRIES STIMULATING THE GLOBAL NEEDLE FREE
DRUG DELIVERY DEVICES MARKET
A Report By-Orion Market Research
3.2. RESTRAINT
OMR2017145

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

3.2.1. COMPLEX REGULATORY FRAMEWORK


3.2.2. LIMITATIONS IN TERMS OF RANGE OF APPLICATIONS
3.2.3. HIGH PRICES
3.2.4. LOW AWARENESS
3.3. OPPORTUNITY
3.3.1. GROWING ASIA PACIFIC REGION
3.3.2. RISING DEMAND OF SELF-ADMINISTRATION OF DRUGS
3.3.3. INCREASING FOCUS ON THE DEVELOPMENT OF PORTABLE DELIVERY DEVICES
3.3.4. RISING DEMAND FOR BIOSIMILARS AND VACCINATIONS
4. MARKET SEGMENTATION
4.1. NEEDLE FREE DRUG DELIVERY DEVICES, BY TECHNOLOGY
4.1.1. ORAL DRUG DELIVERY SYSTEM
4.1.2. INHALER TECHNOLOGY
4.1.3. LASER BASED NEEDLE FREE INJECTORS
4.1.4. JET INJECTORS
4.1.5. NOVEL NEEDLE FREE TECHNOLOGIES
4.1.6. SPRING BASED NEEDLE FREE INJECTORS
4.1.7. TRANSDERMAL PATCH TECHNOLOGY
4.1.8. OTHER NEEDLE FREE TECHNOLOGY
4.2. NEEDLE FREE DRUG DELIVERY DEVICES, BY APPLICATION
4.2.1. PAIN MANAGEMENT
4.2.2. INSULIN DELIVERY FOR DIABETES
4.2.3. VACCINE DELIVERY
4.2.4. PAEDIATRIC INJECTIONS
4.2.5. OBSTRUCTIVE SLEEP APNEA
4.2.6. OTHER APPLICATIONS
4.2.6.1. HYPERTENSION
4.2.6.2. ANGINA
4.2.6.3. OTHER MEDICAL CONDITIONS
4.3. NEEDLE FREE DRUG DELIVERY DEVICES, BY END USER
4.3.1. HOSPITALS
4.3.2. HOME HEALTHCARES
4.3.3. CLINICS
4.3.4. OTHERS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

5.2. KEY COMPANY ANALYSIS


6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS
6.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS
6.1.2. CANADA MARKET RESEARCH AND ANALYSIS
6.2. EUROPEAN MARKET RESEARCH AND ANALYSIS
6.2.1. UK MARKET RESEARCH AND ANALYSIS
6.2.2. GERMANY MARKET RESEARCH AND ANALYSIS
6.2.3. SPAIN MARKET RESEARCH AND ANALYSIS
6.2.4. FRANCE MARKET RESEARCH AND ANALYSIS
6.2.5. ITALY MARKET RESEARCH AND ANALYSIS
6.2.6. ROE MARKET RESEARCH AND ANALYSIS
6.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS
6.3.1. INDIA MARKET RESEARCH AND ANALYSIS
6.3.2. CHINA MARKET RESEARCH AND ANALYSIS
6.3.3. JAPAN MARKET RESEARCH AND ANALYSIS
6.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS
6.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS
7. COMPANY PROFILES
7.1. 3M
7.1.1. INTRODUCTION
7.1.2. 3 M PRODUCT PORTFOLIO
7.1.3. 3 M RECENT ACTIVITIES
7.2. AKRA DERMOJET INC
7.2.1. INTRODUCTION
7.2.2. AKRA DERMOJET INC PRODUCT PORTFOLIO
7.2.3. AKRA DERMOJET INC ZO NOBEL NV RECENT ACTIVITIES
7.3. ANTARES PHARMA INC.
7.3.1. INTRODUCTION
7.3.2. ANTARES PHARMA INC.PRODUCT PORTFOLIO
7.3.3. ANTARES PHARMA INC. RECENT ACTIVITIES
7.4. BAYER AG
7.4.1. INTRODUCTION
7.4.2. BAYER AG PRODUCT PORTFOLIO
7.4.3. BAYER AG RECENT ACTIVITIES
7.5. BIOJECT MEDICAL TECHNOLOGIES, INC.

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

7.5.1. INTRODUCTION
7.5.2. BIOJECT MEDICAL TECHNOLOGIES, INC. PRODUCT PORTFOLIO
7.5.3. BIOJECT MEDICAL TECHNOLOGIES, INC. RECENT ACTIVITIES
7.6. GLAXOSMITHKLIN PLC
7.6.1. INTRODUCTION
7.6.2. GLAXOSMITHKLIN PLC PRODUCT PORTFOLIO
7.6.3. GLAXOSMITHKLIN PLC RECENT ACTIVITIES
7.7. GLIDE PHARMACEUTICAL TECHNOLOGIES LTD.
7.7.1. INTRODUCTION
7.7.2. GLIDE PHARMACEUTICAL TECHNOLOGIES LTD. PRODUCT PORTFOLIO
7.7.3. GLIDE PHARMACEUTICAL TECHNOLOGIES LTD. RECENT ACTIVITIES
7.8. INJEX PHARMA AG
7.8.1. INTRODUCTION
7.8.2. INJEX PHARMA AG PRODUCTS AND CHEMICALS PRODUCT PORTFOLIO
7.8.3. INJEX PHARMA AG RECENT ACTIVITIES
7.9. JDRF
7.9.1. INTRODUCTION
7.9.2. JDRF PRODUCT PORTFOLIO
7.9.3. JDRF RECENT ACTIVITIES
7.10. JOHNSON & JOHNSON, INC.
7.10.1. INTRODUCTION
7.10.2. JOHNSON & JOHNSON, INC. PRODUCT PORTFOLIO
7.10.3. JOHNSON & JOHNSON, INC. COMPANY RECENT ACTIVITIES
7.11. MEDTRONIC, INC.
7.11.1. INTRODUCTION
7.11.2. MEDTRONIC, INC. PRODUCT PORTFOLIO
7.11.3. MEDTRONIC, INC. RECENT ACTIVITIES
7.12. MERCK AND CO.
7.12.1. INTRODUCTION
7.12.2. MERCK AND CO. PRODUCT PORTFOLIO
7.12.3. MERCK AND CO. RECENT ACTIVITIES
7.13. NEMERA
7.13.1. INTRODUCTION
7.13.2. NEMERA PRODUCT PORTFOLIO
7.13.3. NEMERA RECENT ACTIVITIES
7.14. NOVARTIS AG

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

7.14.1. INTRODUCTION
7.14.2. NOVARTIS AG PRODUCT PORTFOLIO
7.14.3. NOVARTIS AG RECENT ACTIVITIES
7.15. PANCREUM LLC
7.15.1. INTRODUCTION
7.15.2. PANCREUM LLC PRODUCT PORTFOLIO
7.15.3. PANCREUM LLC RECENT ACTIVITIES
7.16. PFIZER, INC.
7.16.1. INTRODUCTION
7.16.2. PFIZER, INC. PRODUCT PORTFOLIO
7.16.3. PFIZER, INC. RECENT ACTIVITIES
7.17. PHARMAJET, INC.
7.17.1. INTRODUCTION
7.17.2. PHARMAJET, INC. PRODUCT PORTFOLIO
7.17.3. PHARMAJET, INC. RECENT ACTIVITIES
7.18. SANOFI
7.18.1. INTRODUCTION
7.18.2. SANOFI PRODUCT PORTFOLIO
7.18.3. SANOFI RECENT ACTIVITIES
7.19. TANDEM DIABETES CARE, INC.
7.19.1. INTRODUCTION
7.19.2. TANDEM DIABETES CARE, INC. PRODUCT PORTFOLIO
7.19.3. TANDEM DIABETES CARE, INC. RECENT ACTIVITIES
7.20. ZOGENIX, INC.
7.20.1. INTRODUCTION
7.20.2. ZOGENIX, INC. PRODUCT PORTFOLIO
7.20.3. ZOGENIX, INC. RECENT ACTIVITIES

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

REPORT SUMMARY

The market size of the anatomic pathology was estimated to be $XXX million in 2016, and is further
estimated to reach $XX million during the forecast period (2017-2022). Anatomic pathology is a
medical speciality that involves examining tissue specimen taken from human body. The process is
conducted for diagnosis of diseases based on microscopic, macroscopic, biochemical, immunologic,
and molecular examination of organs and tissues. The major application of anatomic pathology is to
identify abnormalities that enable to diagnose and manage treatment of diseases such as cancerous
tumours, autoimmune disorders, kidney and liver diseases, and infections. The rising incidence and
prevalence rate of chronic diseases and increasing disposable income across the globe is boosting
the growth of anatomic pathology market. Additionally, the increasing number of geriatric
population, rising prevalence of infectious disease, and increasing use of biomarkers are also
predicted to drive the market growth.

Stringent regulatory policies and changing requirements, and the U.S. government imposing excise
duty are estimated to be the major constraints in the growth of the market. Federal law classifies
anatomic pathology as high complexity testing. Clinical Laboratory Improvement Amendments (CLIA)
require an associate degree in a related or the equivalent for surgeon performing high complexity
testing. Anyone working in anatomic pathology in the US must meet CLIA requirements for high
complexity testing and need not to be certified. Moreover, improvement in total time taken
(Turnaround time) is another critical element of management and failure to deal with large number
of cancer patients for biopsy are also some of the factors hindering the growth of market. Besides
these constraints, anatomic pathology market is yet to explore to its full potential. Growing Asia
pacific region, rising number of reagent rental agreement, and development in healthcare
infrastructure are developing numerous expansion opportunities for the growth of the market. The
presence of emerging economies like China, India, and Japan, where large population, growing
prevalence of chronic disease are some major factors driving the high growth in the APAC anatomic
pathology market.

The market is segmented into five major segments namely; application, product and services, end-
users, and regional outlook. On the basis of application, the market is segmented into disease
diagnostic, drug discovery, and others application. Disease diagnostic is further segmented into
cancer, lymphoma, and others. On the basis of the end-user, anatomic pathology market is
bifurcated into hospitals, clinical laboratories, physician laboratory, and others. On the basis of
product and services, the anatomic pathology market is segmented into anesthesiology,
consumables, services, and instruments. Furthermore, on the basis of subdivision, the market is
bifurcated into cytopathology and histopathology.

On the basis of geography, the market is divided into North America, Asia Pacific, Europe and Rest of
the world. North America holds the highest market share of global market owing to increasing
investments by government and academic research centers in diagnostic research, prevalence of
lung cancer and other chronic diseases, growing elderly population, the presence of major players in
this region and high attention to biomarkers research. The government initiatives to precisely
specifying healthcare needs by standardizing medical informatics, integrating systems and making
them less expensive and more efficient are the driving factors for the growth of the anatomic

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

pathology in the region. The International Healthcare Enterprise (IHE) Anatomic Pathology initiative
was launched in North America to implement the best use of medical informatics standards for
producing, sharing and exchanging machine readable reports within hospitals and across healthcare
facilities. According to UN (United Nations Org), over the next 15 years, the number of older persons
is expected to grow fastest in the Caribbean and Latin America with a projected 71% increase in the
population aged 60 years or over, followed by North America (41%).The growing chronic and other
life-threatening diseases among the aged population is eventually increasing the demand for
diagnostic and anatomic pathology.

Asia Pacific is expected to witness fastest market growth in the upcoming time period owing to rising
population, which directly increase chronic diseases, the presence of emerging economies such as
India, China, and Japan, improved standards in health care services, growing demand for superior
medical care, and the growing awareness regarding the importance of anatomic pathology
investigation among health practitioners are some of the major factors, which act as a motivators in
the growth of APAC region.

The key players in the global anatomic pathology market include Abbott Diagnostics, Agilent
Technologies, Danaher, Roche Diagnostics, Thermo Fisher Scientific, Abcam, Adnagen, Advanced Cell
Diagnostics, Agendia, Angsana Molecular & Diagnostics Laboratory, Autogenomics, Biocare Medical,
Biocartis, Cellmax Life, Cancer Genetics, Digipath, and Enzo Biochem. Other notable players are Epic
Sciences, Janssen Diagnostic, Monogram Biosciences, Nucleix, Omnyx, Oxford Cancer Biomarkers,
Rarecyte, Sakura Finetek Usa, Tecan, and Volitionrx. These vendors are increasingly competing with
each other based on factors such as mergers, capital support, investment, and research and
development. In 2016, Biocare Medical launched HPV probes to detect HPV DNA viral subtypes 6, 11,
16, 18, 31 or 51. More than 80 million Americans are infected with Human Papilloma Virus (HPV),
with about 14 million becoming newly infected each year. With the introduction of HPV probes, the
company is striving to improve the molecular diagnostic tools available to pathologists.

GLOBAL ANATOMIC PATHOLOGY MARKET RESEARCH AND ANALYSIS, BY REGION 2015-


2022 ($ MILLION)

Region 2015 2016 2017 2018 2019 2020 2021 2022 CAGR%
2017-2022

North America XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX
Europe XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX
Asia pacific XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX
RoW XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX
Total XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX
Source: OMR Analysis

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

RESEARCH METHODS AND TOOLS

Key points considered to derive the numbers:

Geographical analysis
Analysis of the various products, services and application.
Analysis of the type of services and their penetration in the market.
End user analysis.
Average cost analysis at global as well as regional level.
Annual reports of key manufacturers and end users

The data is refined through our secondary and primary research.

A team devoted to track down trends in the industry,


Secondary company documents and financials
Research Studying government and non-government organization,
laws and regulations, tracking down policies and tax laws.

A team of experts refines all the data available to derive


Refining Secondary
the market segments, share of each market segment, total
Data
market size and final CAGR.

Primary researh involves tracking down key people from


the industry and interviewing them to validate the data.
This enables our analyst to derive the closest possible
Primary Research figures without any major deviations in the actual number.
Our analysts try to contact as many executives, managers,
key opinion leaders and industry experts. Primary research
brings the authenticity in our reports.

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

BY SEGMENTS

The global anatomic pathology market is studied thoroughly by bifurcating into five major segments
namely; application, product and services, end-users, and regional outlook. On the basis of
application, the market is segmented into disease diagnostic, drug discovery, and others. Disease
diagnostic is further segmented into cancer, lymphoma, and others. Disease diagnosis holds the
largest share due to rising prevalence of diseases such as cardiovascular disease, chronic disease,
diabetes and other lifestyle disease. The market is expected to grow at a CAGR of X% from 2017 to
2022.Drug discovery will be the fastest growing market due to the factors such as rising prevalence of
drug resistance and need of vaccines for curing diseases, such as cholera, swine flu, influenza and
other life-threatening diseases.

On the basis of the end-user, the anatomic pathology market is bifurcated into hospitals, clinical
laboratories, physician laboratory, and others. On the basis of product and services, the anatomic
pathology market is segmented into anesthesiology, consumables, services and instruments. Service
segment accounts for the largest share of the market owing to the increasing prevalence of chronic
disease and growth in the number of anatomic pathology tests. Instrument will be the fastest
growing segment throughout the forecast period due to technological advancement in device
designs. Furthermore, on the basis of subdivision, the market is bifurcated into cytopathology and
histopathology.

DRUG DISCOVERY

Drug discovery is the process by which, new medications are discovered. The increasing prevalence
of life threatening diseases such as cancer, diabetes, neurological conditions, coronary heart disease
and HIV/Aids has led to the drug discovery of new drugs. This allows the researchers to design a
product to stop or reverse the effect of drugs. Several medicines have been developed by the
pharmaceutical industry, and the industry continues to invest in research and development. Cancer,
heart disease, diabetes and other lifestyle oriented diseases affect millions of people across the
globe.

FDA APPROVED DRUGS IN 2017


BRANCH DRUG NAME FDA APPROVED USE
Cardiology/Vascular Diseases Bevyxxa (betrixaban) for thromboembolic complications

Dermatology Baxdela (delafloxacin) acute bacterial skin and skin


structure infections
Dupixent (dupilumab) atopic dermatitis

Endocrinology Qtern (dapagliflozin and inadequately controlled type II


saxagliptin) diabetes

Immunotherapy Tecentriq (atezolizumab) Bladder Cancer

Immunotherapy Venclexta (Venetoclax) Chronic Lymphocytic Leukemia

Antiretroviral therapy Emtricitabine HIV infection in adults, children,


and infants.

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

Antiretroviral therapy Atazanavir for the treatment of HIV infection


in adults
Source: FDA, OMR Analysis

New medicines have led to the improved treatment of cancer, hypertension, and AIDS, while certain
medicines have slowed down the conditions such as Alzheimers disease or arthritis. There are 52
medicines and vaccines for HIV currently in development that includes additional combination
treatments, more effective therapies, and preventative vaccines. These medicines as well as vaccines
are either in clinical trials or are awaiting approval by the FDA. Among the 52 medicines in
development for HIV, there are 32 antiretrovirals and antivirals, 16 vaccines and four cell therapies to
prevent HIV from attaching to new cells and breaking through the cell membrane. 600,000 US cancer
deaths were estimated in 2017. More than 4.8% of the US population are cancer survivor and 87% of
cancer diagnoses in the U.S. are in people age 50 or older. More than 240 immuno-oncology
treatments in development are accelerating progress for patients with cancer. CAR-T therapy,
checkpoint modulators, and oncolytic virus therapies are advances in cancer immunotherapy.

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

MOTIVATOR

INCREASING NUMBER OF GERIATRIC POPULATION

Aging population is increasing at a very fast pace, according to WHO, between 2000 and 2050, the
proportion of the world's population over 60 years will double from about 11% to 22%. The absolute
number of people aged 60 years and above is expected to increase from 605 million to two billion
over the same period. The number of people aged 80 years or older will have quadruple between
2000 and 2050 to 395 million. According to UN (United Nations Org) over the next 15 years, the
number of elder people is expected to grow fastest in the Caribbean and Latin American region with
a projected 71 % increase in the population aged 60 years or more, followed by Asia (66 %), Africa
(64%), Oceania (47%), Northern America (41%) and Europe (23%).

The rising population with the lack of proper healthcare sanitation facilities is contributing to spread
of infectious diseases. Cardiovascular diseases (CVDs) are predicted to be one of the major causes of
mortality across the globe, accounting for more than 17.3 million mortalities per year. The number of
mortality by CVD is further estimated to reach 23.6 million by 2030. CVD accounts for 31% of global
mortality in 2013, of which 80% of mortalities occurred are in low and middle-income countries. In
2013, cardiovascular disease is the cause of 801,000 mortality in the US alone. Heart Disease is the
leading cause of mortality across the globe, and about 370,000 Americans die every year due to
CVDs. Direct and indirect cost associated with the CVD is estimated to be approximately 316.6 billion.
Moreover, Cancer is also one of the leading causes of mortality across the globe. According to world
cancer society, an estimated 1.6 million new cases of cancer will be diagnosed in the U.S. and
595,690 people will die from the disease. Around 39.6% of men and women will be diagnosed with
cancer at some point during their lifetimes.

The global anatomic pathology market is growing significantly owing to the increasing incidence and
prevalence rate of chronic diseases including kidney or liver diseases, infectious diseases, and cancer.
Cancer cases are growing exponentially across the globe, with maximum patients suffering from
colorectal, lung, prostate, and breast cancer. Biomarkers is a promising approach used for the
diagnosis of cancer and other diseases. The elevating use of biomarkers for the diagnosis of diseases
is predicted to considerably accelerate the development of the anatomic pathology market.
Additionally, developing healthcare infrastructure and the growing elderly population also play a
contributing role, as elderly persons are prone to infectious diseases. Thus, the demand for proper
diagnosis and effective treatment also increases leading to the growth of anatomic pathology in the
market.

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

COMPANY PROFILE

OXFORD CANCER BIOMARKERS

The Magdalen Centre


Oxford Science Park
Robert Robinson Avenue
Oxford, OX4 4GA
UK
Phone: +441865784743
Website: www.oxfordbio.com

INTRODUCTION

Oxford cancer biomarker was founded in 2010 and is based in the US. The company develops and
commercializes biomarkers tests that provide effective treatment for cancer patients. It also offers
drug specific diagnostic kit that enables biomarkers to be directly measured in tumor biopsies and
thereby patients that respond favorably to the drug identified. The company biomarker test includes
ColoTox, ColoProg, ColoPredict, and ColoNav. Furthermore, the company developed two biomarker
platforms for companion diagnostic development.

OXFORD CANCER BIOMARKERS PRODUCT PORTFOLIO

Product Description
ColoTox The product identifies high risk of severe drug side-effects and therefore used by
clinicians to select safer chemotherapy drug doses. It also identifies small set of
patients that should avoid 5FU based chemotherapy due to high risk of toxic death.

ColoProg The product identifies patients requiring chemotherapy. A test is carried out after
colorectal cancer surgery to identify patients who are at low risk, high risk or
standard risk of healing process. This test enables surgeons and oncologists to target
chemotherapy only to those patients who are at higher risk of relapse and avoid
using chemotherapy to those patients who can easily be cured by surgery alone.
ColoNav The product predicts if patients colorectal cancer will respond to fluorouracil
chemotherapy. This enables surgeons and oncologist to make decisions about the use
of fluoropyrimidine adjuvant chemotherapy.

ColoPredict The product identifies subpopulation of healthy individuals who are at risk of
developing colorectal cancer so that they can minimize the risk of cancer. ColoPredict
is performed on DNA collected from simple mouth swab as it is the cost-effective test
to determine cancer.

Source: Company Website

OXFORD CANCER BIOMARKERS RECENT ACTIVITIES

Date Activity Details

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

Sept, 2017 Collaboration Oxford Cancer Biomarkers and Ningbo My-BioMed Biotechnology Co. Ltd
(MBM) collaborated to establish joint laboratories in Ningbo Meishan and
Oxford and participated together in several research and development
programs.

Apr, 2017 Collaboration Oxford Cancer Biomarkers collaborated with My-BioMed Biotechnology
Co. Ltd. to allow My-BioMed Biotechnology Ltd to access OCBs ColoTox,
ColoProg, and ColoPredict technologies.

Nov, 2016 Product launch Oxford Cancer Biomarkers Ltd (OCB) partnered with Room4 to develop
new prognostic biomarkers for colorectal cancer to use in OCBs ColoProg
test.

Source: Company Website

All Rights Reserved


Global Anatomic Pathology Market Research and Analysis 2015-2022

Orion Market Research

ABOUT US

Orion Market Research provides market research and consulting services. At OMR we strive
to deliver quality reports that are based on a 360degree analysis of the market factors. We
provide qualitative and quantitative analysis of the market. We serve clients from 16
different domains which includes healthcare, biotechnology, chemical, agriculture and
information technology. We work to add more to our array of clients, services and products.
At the moment OMR provides 4 services;
i. Industry Reports
ii. Consulting
iii. Custom Reports
iv. Company Profiling
Market research and consulting is a highly competitive market. There are number of
companies which provide top quality reports and analysis. At OMR we believe in overcoming
the competition by delivering timely and quality reports. The Orion in our names signifies our
attempt to create a place for ourselves amongst a galaxy of market research companies.
Thank You for being with us and believing in us.

CONTACT US

Orion Market Research Pvt Ltd


116, Shagun Arcade
Indore, Madhya Pradesh
India- 452001

Email: info@omrglobal.com Website: www.omrglobal.com Phone: +91-9179828694

All Rights Reserved

Anda mungkin juga menyukai